Enanta Pharmaceuticals, Inc. Announces Financial Results for the Second Fiscal Quarter and Six Months Ended March 31, 2013
5/8/2013 8:02:37 AM
More...
|
Enanta Pharmaceuticals, Inc. Release: Breakthrough Therapy Designation From the FDA Granted to Investigational HCV Regimen Containing Protease Inhibitor ABT-450
5/6/2013 10:01:27 AM
More...
|
Enanta Pharmaceuticals, Inc. Announces New Data From Phase 2b Interferon-Free Combination Studies With Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL
4/23/2013 12:19:20 PM
More...
|
Enanta Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option
3/27/2013 9:10:52 AM
More...
|
Enanta Pharmaceuticals, Inc. Raises $56 Million in IPO
3/21/2013 10:59:24 AM
More...
|
TetraPhase Pharmaceuticals, Enanta Pharmaceuticals, Inc. Prepare for IPOs
3/19/2013 8:39:44 AM
More...
|
Enanta Pharmaceuticals, Inc. Files Registration Statement for Proposed Initial Public Offering
11/7/2012 10:04:58 AM
More...
|
Enanta Pharmaceuticals, Inc.'s Lead Hep. C Compound ABT-450 Advances Into a Phase 3 Trial With Abbott Laboratories (ABT)
10/17/2012 10:44:53 AM
More...
|
Enanta Pharmaceuticals, Inc. Announces Positive Phase 2 Results From Interferon-Free Combination Studies With ABT-450 for Hepatitis C Treatment to be Presented at EASL
4/4/2012 11:21:16 AM
More...
|
Enanta Pharmaceuticals, Inc. Strikes Hep C Drug Deal With Novartis AG (NVS) Worth Up to $440 Million
2/21/2012 7:39:23 AM
More...
|
|